Bristol Myers Squibb (CELG-RI) Free Cash Flow Growth (1y) (2010 - 2026)
Bristol Myers Squibb (CELG-RI) Free Cash Flow Growth (1y) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 157.32% |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -36.24% |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 77.03% |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | -12.19% |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | -22.41% |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 82.57% |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 376.81% |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 125.17% |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 28.86% |
| 10 | Bristol Myers Squibb | 224.21 Mn | -10.84 Bn | 9.25 Bn | -13.16% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -13.16% |
| Mar 31, 2026 | -55.31% |
| Dec 31, 2025 | -60.50% |
| Sep 30, 2025 | 13.75% |
| Jun 30, 2025 | 72.29% |
| Mar 31, 2025 | -33.57% |
| Dec 31, 2024 | 3.54% |
| Sep 30, 2024 | 19.46% |
| Jun 30, 2024 | 26.78% |
| Mar 31, 2024 | -5.27% |
| Dec 31, 2023 | 32.50% |
| Sep 30, 2023 | 28.17% |
| Jun 30, 2023 | -18.15% |
| Mar 31, 2023 | -24.36% |
| Dec 31, 2022 | -20.79% |
| Sep 30, 2022 | -31.14% |
| Jun 30, 2022 | -30.21% |
| Mar 31, 2022 | -2.52% |
| Dec 31, 2021 | 21.65% |
| Sep 30, 2021 | 136.33% |